Humanized mouse models for immuno-oncology research

Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(3), P. 192 - 206

Published: Jan. 12, 2023

Language: Английский

---

CAR-T cell manufacturing: Major process parameters and next-generation strategies

The Journal of Experimental Medicine, Journal Year: 2024, Volume and Issue: 221(2)

Published: Jan. 16, 2024

Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment CAR-T to treat hematologic solid cancers, as well other indications such autoimmune diseases, is dependent on effective manufacturing that impacts not only product safety efficacy but also overall accessibility patients need. In this review, we discuss major process parameters autologous manufacturing, regulatory considerations ongoing developments will enable next generation therapies.

Language: Английский

---

Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy

Trends in biotechnology, Journal Year: 2023, Volume and Issue: 41(7), P. 907 - 922

Published: Feb. 28, 2023

Language: Английский

---

Single-cell senescence identification reveals senescence heterogeneity, trajectory, and modulators

Cell Metabolism, Journal Year: 2024, Volume and Issue: 36(5), P. 1126 - 1143.e5

Published: April 10, 2024

Language: Английский

---

The immunology of systemic lupus erythematosus

Nature Immunology, Journal Year: 2024, Volume and Issue: 25(8), P. 1332 - 1343

Published: July 15, 2024

Language: Английский

---

Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism

Cell Reports Medicine, Journal Year: 2024, Volume and Issue: 5(2), P. 101400 - 101400

Published: Feb. 1, 2024

Chimeric antigen receptor (CAR)-T therapy has shown superior efficacy against hematopoietic malignancies. However, many patients failed to achieve sustainable tumor control partially due CAR-T cell exhaustion and limited persistence. In this study, by performing single-cell multi-omics data analysis on patient-derived cells, we identify CD38 as a potential hallmark of exhausted which is positively correlated with exhaustion-related transcription factors further confirmed in vitro models. Moreover, inhibiting activity reverses tonic signaling- or antigen-induced independent single-chain variable fragment design costimulatory domain, resulting improved cytotoxicity antitumor response. Mechanistically, inhibition synergizes the downregulation CD38-cADPR -Ca2+ signaling activation CD38-NAD+-SIRT1 axis suppress glycolysis. Collectively, our findings shed light role suggest clinical applications enhancing persistence therapy.

Language: Английский

---

Generating human bone marrow organoids for disease modeling and drug discovery

Nature Protocols, Journal Year: 2024, Volume and Issue: 19(7), P. 2117 - 2146

Published: March 26, 2024

Language: Английский

---

EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models

Cancer Cell, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

---

Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies

Blood, Journal Year: 2022, Volume and Issue: 141(8), P. 846 - 855

Published: Nov. 3, 2022

The development of methods to derive induced pluripotent stem cells (iPSCs) has propelled cell research, and the potential revolutionize many areas medicine, including cancer immunotherapy. These can be propagated limitlessly differentiate into nearly any specialized type. ability perform precise multigene engineering at iPSC stage, generate master lines after clonal selection, faithfully promote differentiation along natural killer (NK) T-cell lineages is now leading new opportunities for administration off-the-shelf cytotoxic lymphocytes with direct antigen targeting treat patients relapsed/refractory cancer. In this review, we highlight recent progress in editing guided NK- products We also discuss some barriers that remain unleashing full iPSC-derived effector adoptive transfer setting, how these limitations may overcome through gene editing.

Language: Английский

---

Advancing cell-based cancer immunotherapy through stem cell engineering

Cell stem cell, Journal Year: 2023, Volume and Issue: 30(5), P. 592 - 610

Published: March 21, 2023

Advances in cell-based therapy, particularly CAR-T cell have transformed the treatment of hematological malignancies. Although an important step forward for field, autologous therapies are hindered by high costs, manufacturing challenges, and limited efficacy against solid tumors. With ongoing progress gene editing culture techniques, engineered stem cells their application therapy poised to address some these challenges. Here, we review immunotherapy approaches, sources, engineering strategies, therapeutic platforms, clinical trials, as well challenges future directions field.

Language: Английский

---